Literature DB >> 6350880

Divalent cations in essential hypertension. Relations between serum ionized calcium, magnesium, and plasma renin activity.

L M Resnick, J H Laragh, J E Sealey, M H Alderman.   

Abstract

We studied the relation of plasma renin activity to serum levels of ionized calcium and magnesium in 102 normotensive patients and in 98 patients with essential hypertension who were divided into low-renin, normal-renin, and high-renin groups. Serum magnesium levels were higher in patients with low-renin hypertension and lower in patients with high-renin hypertension than in those with normal-renin hypertension (P less than 0.025 for both comparisons) or in normotensive controls (P less than 0.005, P less than 0.05, respectively). In contrast, serum levels of ionized calcium were lower in patients with low-renin hypertension and higher in patients with high-renin hypertension than in those with normal-renin hypertension (P less than 0.001, P less than 0.05, respectively) or in normotensive controls (P less than 0.001, P less than 0.05, respectively). Altogether, the range of plasma renin activity in essential hypertension shows a continuous negative correlation with the serum magnesium level (r = -0.60, P less than 0.001) and a positive correlation with the serum ionized calcium level (r = 0.44, P less than 0.001). Accordingly, plasma renin activity in hypertension may reflect or contribute to changes in calcium and magnesium fluxes across cell membranes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6350880     DOI: 10.1056/NEJM198310133091504

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  35 in total

Review 1.  The role of calcium in the prevention of cardiovascular disease--a review of observational studies and randomized clinical trials.

Authors:  Susanne Rautiainen; Lu Wang; JoAnn E Manson; Howard D Sesso
Journal:  Curr Atheroscler Rep       Date:  2013-11       Impact factor: 5.113

Review 2.  Calcium intake and risk of cardiovascular disease: a review of prospective studies and randomized clinical trials.

Authors:  Lu Wang; JoAnn E Manson; Howard D Sesso
Journal:  Am J Cardiovasc Drugs       Date:  2012-04-01       Impact factor: 3.571

3.  Low Calcium Intake in Midpregnancy Is Associated with Hypertension Development within 10 Years after Pregnancy: The Norwegian Mother and Child Cohort Study.

Authors:  Grace M Egeland; Svetlana Skurtveit; Solveig Sakshaug; Anne Kjersti Daltveit; Bjørn E Vikse; Margaretha Haugen
Journal:  J Nutr       Date:  2017-07-12       Impact factor: 4.798

4.  Meta-analysis of hypertension and osteoporotic fracture risk in women and men.

Authors:  C Li; Y Zeng; L Tao; S Liu; Z Ni; Q Huang; Q Wang
Journal:  Osteoporos Int       Date:  2017-04-26       Impact factor: 4.507

Review 5.  Nutritional aspects of pediatric hypertension.

Authors:  J R Ingelfinger
Journal:  Bull N Y Acad Med       Date:  1989-12

6.  Calcium channel blockade: an alternative to diuretic therapy.

Authors:  J P Nicholson; L M Resnick; J Laragh
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

Review 7.  Endocrine physiology of electrolyte metabolism.

Authors:  K G Dawson
Journal:  Drugs       Date:  1984-10       Impact factor: 9.546

8.  Parathyroid hormone in coronary artery disease--results of a prospective study.

Authors:  G Herrmann; R Hehrmann; H C Scholz; M Atkinson; P Lichtlen; A von zur Mühlen; R D Hesch
Journal:  J Endocrinol Invest       Date:  1986-08       Impact factor: 4.256

9.  Intracellular ionic consequences of dietary salt loading in essential hypertension. Relation to blood pressure and effects of calcium channel blockade.

Authors:  L M Resnick; R K Gupta; B DiFabio; M Barbagallo; S Mann; R Marion; J H Laragh
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

Review 10.  Diltiazem. A review of its pharmacology and therapeutic use in older patients.

Authors:  A Markham; R N Brogden
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.